SABCS 2024 | Reevaluating sentinel node biopsy post-neoadjuvant treatment in breast cancer

Johannes Holtschmidt • 12 Dec 2024

SABCS 2024

Johannes Holtschmidt, MD, German Breast Group, Neu-Isenburg, Germany, provides an overview of the challenges in accurately identifying residual node-positive breast cancer patients after neoadjuvant systemic treatment. Despite 20–30% of patients being node-positive at baseline, fewer than 3% remain so after treatment, yet current imaging lacks reliability in pinpointing these individuals. Subsequently, there is a need for improved detection methods to accurately stratify patients and guide therapeutic decisions, including adjuvant pertuzumab, to optimize outcomes for high-risk groups. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.